Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2014

View Archived Issues

Researchers confirm ambidextrous chaperone activity of GroEL/ES

Alirocumab lowers the rate of major CV events in patients with hypercholesterolemia

4D pharma profiles pipeline progress

Jakavi launched in Japan

APD-811 granted FDA orphan drug status for pulmonary arterial hypertension

FDA grants fast track designation to motolimod for ovarian cancer

Xention and Servier begin first phase II study of XEN-D0103

Ozurdex approved in the E.U. for the treatment of diabetic macular edema

HanAll BioPharma discloses new AMPK activators

Zytiga launched in Japan for prostate cancer

FDA accepts NDA filing for eluxadoline, grants priority review

Novel NS5B inhibitors disclosed by Bristol-Myers Squibb

Amgen submits MAAs for talimogene laherparepvec and evolocumab in the E.U.

Merck & Co. synthesizes novel IRAK inhibitors

Reslizumab reduces asthma exacerbations in two pivotal phase III trials

Mitsubishi Tanabe Pharma and Daiichi Sankyo launch Canaglu in Japan

Draconis Pharma patents new EP4 receptor antagonists

Opdivo launched in Japan for unresectable melanoma

Nuplazid receives FDA breakthrough therapy designation for Parkinson's disease psychosis

Hua Medicine patents new mGlu5 receptor antagonists

Lundbeck launches Northera in U.S. for symptomatic neurogenic orthostatic hypotension

Final results of PARADIGM-HF and other studies presented for LCZ-696

Kaken launches Clenafin in Japan for tinea unguium

European orphan drug designations for CER-001 in apoA-I and ABCA1 deficiencies

Methotrexate receives FDA orphan drug status for myasthenia gravis

Phase II results for EPI-743 in Rett syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...